positioning Simparica Trio for continued dominance. Guidance reflects foreign exchange headwinds of approximately $250 million to revenue and $50 million to adjusted net income. Zoetis reported Q4 ...

Q4 2024 Earnings Call Transcript February 13, 2025 Zoetis Inc. beats earnings expectations. Reported EPS is $1.4, ...

Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...

Zoetis Inc (ZTS) reports robust financial performance with significant growth in companion animal products and strategic ...

Zoetis said the U.S. Department of Agriculture's Center for Veterinary Biologics issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is ...

Coming up: In 2025, Zoetis is set to face more direct competition for some its flagship therapies, including Apoquel and Simparica Trio. It's not clear that rival Elanco's new entrants (Zenrelia ...

as well as Zoetis’ parasiticide products, such as Simparica and the Simparica Trio. Livestock product sales were flat year over year on a reported basis and grew 6% operationally to $477 million.

Q4 2024 Management View CEO Kristin Peck highlighted Zoetis delivered an excellent 2024, achieving double-digit operational revenue growth of 11% and adjusted net income growth of 15%. U.S. and ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsSteve Frank - IRKristin Peck - CEOWetteny Joseph ...

Librela for dogs and Solensia for cats, dermatology products like Apoquel and Cytopoint, as well as Zoetis’ parasiticide products, such as Simparica and the Simparica Trio.